Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Jan 21;17(1):e0262931.
doi: 10.1371/journal.pone.0262931. eCollection 2022.

Prognostic significance of SHP2 (PTPN11) expression in solid tumors: A meta-analysis

Jiupeng Zhou  1 , Hui Guo  1   2 , Yongfeng Zhang  1 , Heng Liu  1 , Quanli Dou  1
Affiliations
Meta-Analysis

Prognostic significance of SHP2 (PTPN11) expression in solid tumors: A meta-analysis

Jiupeng Zhou et al. PLoS One. .

Abstract

Background: SHP2 is a latent biomarker for predicting the survivals of solid tumors. However, the current researches were controversial. Therefore, a meta-analysis is necessary to assess the prognosis of SHP2 on tumor patients.

Materials and methods: Searched in PubMed, EMBASE and web of science databases for published studies until Jun 20, 2021. A meta-analysis was performed to evaluate the affect of SHP2 in clinical stages, disease-free survival (DFS) and overall survival (OS) in tumor patients.

Results: This study showed that the expression of SHP2 had no significant correlation with clinical stages (OR: 0.91; 95% CI, 0.60-1.38; P = 0.65), DFS (HR = 0.88; 95%CI: 0.58-1.34; P = 0.56) and OS (HR = 1.07, 95%CI: 0.79-1.45, P = 0.67), but the prognostic effect varied greatly with tumor sites. High SHP2 expression was positively related to early clinical stage in hepatocellular carcinoma, not associated with clinical stage in the most of solid tumors, containing laryngeal carcinoma, pancreatic carcinoma and gastric carcinoma, etc. Higher expression of SHP2 could predict longer DFS in colorectal carcinoma, while predict shorter DFS in hepatocellular carcinoma. No significant difference was observed in DFS for non-small cell lung carcinoma and thyroid carcinoma. Higher SHP2 expression was distinctly related to shorter OS in pancreatic carcinoma and laryngeal carcinoma. The OS of the other solid tumors was not significantly different.

Conclusions: The prognostic value of SHP2 might not equivalent in different tumors. The prognostic effect of SHP2 is highly influenced by tumor sites.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. A flowchart describing the procedures of document retrieval and selection.
Fig 2
Fig 2. A forest plot for the association between SHP2 expression levels with clinical stage.
Fig 3
Fig 3. A forest plot for the association between SHP2 expression levels with DFS.
Fig 4
Fig 4. A forest plot for the association between SHP2 expression levels with with OS.
Fig 5
Fig 5. Summary risk estimates of clinical stage by cancer sites.
Fig 6
Fig 6. Summary risk estimates of DFS by cancer sites.
Fig 7
Fig 7. Summary risk estimates of OS by cancer sites.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68: 7–30. doi: 10.3322/caac.21442 - DOI - PubMed
    1. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, et al.. (2019) Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 69: 363–385. doi: 10.3322/caac.21565 - DOI - PubMed
    1. Keilhack H, David FS, McGregor M, Cantley LC, Neel BG (2005) Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem 280: 30984–30993. doi: 10.1074/jbc.M504699200 - DOI - PubMed
    1. Miyamoto D, Miyamoto M, Takahashi A, Yomogita Y, Higashi H, et al.. (2008) Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors. Oncogene 27: 3508–3515. doi: 10.1038/sj.onc.1211019 - DOI - PubMed
    1. Loyo M, Pai SI (2008) The molecular genetics of laryngeal cancer. Otolaryngol Clin North Am 41: 657–672, v. doi: 10.1016/j.otc.2008.01.019 - DOI - PubMed

MeSH terms

Substances